ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Adma Biologics (ADMA) to Report a Decline in Earnings: What to Look Out for

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an exclusive educational event at IDWeek 2020 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Lisa Forbes Satter from Baylor College of Medicine and Texas Children's Hospital, as well as new data on Streptococcus pneumonia in an on-demand poster session.

ADMA Biologics Announces Presentation on Respiratory Viral Infections and New Data on S. Pneumoniae at IDWeek 2020

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in ADMA Biologics (ADMA) Stock?

ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

ADMA Biologics (ADMA) Surges: Stock Moves 8.6% Higher

RAMSEY, N.J. and BOCA RATON, Fla., Sept.  09, 2020  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Virtual Healthcare Conference on Monday, September 14, 2020, at 4:30 p.m. ET.

ADMA Biologics to Participate in Morgan Stanley Virtual Healthcare Conference

ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify High Titer Convalescent Plasma for Use in Both Treating COVID-19 Patients and for Creating COVID-19 Hyperimmune Globulins

ADMA Biologics Highlights Launch of COVID-19 ImmunoRank™ Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma

RAMSEY, N.J. and BOCA RATON, Fla., Sept.  02, 2020  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences in September:

ADMA Biologics to Participate in Upcoming Investor Conferences

AstraZeneca

BioNTech SE

Cerus

Liminal BioSciences

Pfizer

Sonnet BioTherapeutics

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Biotech Boom: The Race for COVID-19 Vaccines

Investors need to pay close attention to ADMA stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in ADMA Stock?

Shares of ADMA Biologics are on the move following the FDA's authorization of convalescent plasma for the treatment of COVID-19 patients.

Is ADMA Biologics a Good Coronavirus Stock to Buy Now?

Emergent BioSolutions

Kamada

Convalescent plasma holds promise for treating COVID-19, but it's still unproven.

What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: ADMA Biologics

Grifols, S.A.

ThermoGenesis Holdings, Inc

T2 Biosystems

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.

These Plasma Stocks Are Surging After FDA's Convalescent EUA

iBio

The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.

Why ADMA Biologics, iBio, and Kamada Are Jumping Today

ADMA Biologics has shown substantial progress of late, opening another plasma collection facility and growing sales 78% in H1 2020 over the prior year.

ADMA Biologics Is A Bargain Again After Recent Sell-Off

Aphria

Earthstone Energy

Falcon Minerals Corp

QuickLogic

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Stocks Trading Under $5 With Massive Upside Potential

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2020 Results - Earnings Call Transcript

Adma Biologics (ADMA) delivered earnings and revenue surprises of -21.05% and -24.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q2 Loss, Lags Revenue Estimates

Generated Total Revenues of $18.0 Million for the First Half of 2020, Reflecting a 78% Increase Over First Half of 2019

ADMA Biologics Reports Business Highlights and Second Quarter 2020 Financial Results

Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET

ADMA Biologics to Report Business Highlights and Second Quarter 2020 Financial Results on August 5, 2020

Is the Options Market Predicting a Spike in ADMA Stock?

RAMSEY, N.J. and BOCA RATON, Fla. and KNOXVILLE, Tenn., July  06, 2020  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Knoxville, TN.  ADMA also announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for this second plasma collection center.

ADMA Biologics Opens Its Newest ADMA BioCenters Plasma Collection Facility

ADMA Biologics: Benefit From Production Ramp

RAMSEY, N.J. and BOCA RATON, Fla., June  23, 2020  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the proposed resolution to elect Martha J. Demski to its Board of Directors was approved at the Company’s recent Annual Shareholder Meeting, held June 18, 2020. 

News for ADMA Biologics Stock (ADMA)